Results 211 to 220 of about 39,039 (378)

Recombinant approaches to IgG-like bispecific antibodies [PDF]

, 2005
Jonathan S. Marvin, Zhenping Zhu
openalex   +1 more source

Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review

European Journal of Haematology, EarlyView.
ABSTRACT Objectives The objective of this systematic literature review (SLR) combined with expert clinical review was to identify and rank prognostic factors and effect measure modifiers (EMMs) systematically and comprehensively in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who initiate treatment after ≥ 2 prior ...
Bastian von Tresckow, Pau Abrisqueta, Irene Zamanillo, Ángel Serna Pareja, Yuting Kuang, Jennifer Uyei, Mohsin Shah, Laura Walsh, Eileen Thorley, Krystal Cantos, Emaan Rashidi, Christian Hampp, Jessica J. Jalbert, Alexi N. Archambault, Yingxin Xu, Shivani Aggarwal, Srikanth Ambati, Hesham Mohamed, Qiufei Ma, Ana Jiménez‐Ubieto   +19 more
wiley   +1 more source

Temporal trends in relative survival of diffuse large B‐cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies

British Journal of Haematology, EarlyView.
Sara Harrysson, Sandra Eloranta, Stefanie Antonilli, Mikkel Runason Simonsen, Kristina Sonnevi, Peter Brown, Bjorn E. Wahlin, Per‐Ola Andersson, Judit M. Jørgensen, Mats Jerkeman, Christian B. Poulsen, Gunilla Enblad, Tarec C. El‐Galaly, Karin E. Smedby   +13 more
wiley   +1 more source

Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Bendamustine‐rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B‐cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B‐cell (Hodgkin) lymphoma (NLPBL).
Alexander Robin, Carolyn Owen, Sarah Perry, Lesley Street, Neil Chua, Douglas Stewart, Robert Puckrin   +6 more
wiley   +1 more source

Successful targeting of multidrug-resistant tumors with bispecific antibodies. [PDF]

MAbs
Briante R, Zhai Q, Mohanty S, Zhang P, O'Connor A, Misker H, Wang W, Tan C, Abuhay M, Morgan J, Theolis R, Ponath P, Arathoon R.   +12 more
europepmc   +1 more source

Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct [PDF]

, 2007
Scott A. Hammond, Ralf Lutterbuese, Shannon Roff, Petra Lutterbuese, Bernd Schlereth, Elizabeth Bruckheimer, Michael S. Kinch, Steve Coats, Patrick A. Baeuerle, Peter Kufer, Peter A. Kiener   +10 more
openalex   +1 more source

Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application

The FEBS Journal, EarlyView.
Multiple myeloma is characterised by the clonal proliferation of plasma cells in the bone marrow. Extracellular vesicles (EVs) are a key component of cell‐to‐cell communication within the bone marrow microenvironment, promoting tumour growth, bone remodelling, immune modulation, angiogenesis and therapeutic resistance.
Chloe Wylie, Rebecca Rowan, Dessi Malinova, Lisa Crawford   +3 more
wiley   +1 more source

Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward? [PDF]

Front Immunol
Yan Y, Yuan J, Peng Y, Zhou C, Liu X, Sun L, Song Q.   +6 more
europepmc   +1 more source

Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin [PDF]

, 2007
Dafne Müller, Anette Karle, Bettina Meißburger, Ines Höfig, Roland Stork, Roland E. Kontermann   +5 more
openalex   +1 more source

Haemophilia Prophylaxis in the Age of Innovation: Exploring Opportunities for Personalized Treatment

Haemophilia, EarlyView.
ABSTRACT Introduction Recent advancements in haemophilia treatment have introduced a range of innovative therapies, including activated FVIII mimetics, ultra‐extended half‐life recombinant FVIII, rebalancing agents and gene therapy. These developments have transformed treatment options and expanded prophylaxis strategies.
Yesim Dargaud, Fabienne Volot, Stephanie Desage, Claire Pouplard, Valerie Chamouard, Anne Lienhart   +5 more
wiley   +1 more source